Teams apply broad checks without distinguishing the fields and processes that materially affect participant safety, primary endpoints or key trial decisions.
Healthcare & Life Sciences · Clinical Trial Data Quality
Clinical Trial Data Quality That Holds Up From First Capture to Analysis and Submission
DataConsultant helps sponsors, research organisations and life-sciences teams identify critical trial data, map end-to-end data flows, design risk-proportionate quality rules and controls, improve reconciliation and lineage, and establish measurable operating practices for dependable clinical research data.
✓Critical-to-quality data and risk prioritisation
✓EDC, eSource and external vendor data flows
✓Rules, reconciliation, lineage and evidence
✓Implementation and ongoing quality operations
Scope is tailored by study portfolio, trial phase, systems, vendors, jurisdictions, data criticality, quality risks and required implementation depth. Regulatory interpretation and formal GCP or legal assurance remain with appropriately qualified client and specialist functions.
Clinical Trial Data Quality Control PlaneIllustrative enterprise flow · controls are tailored to the protocol, data sources and intended use
Risk-proportionate
CaptureParticipant, Site & ProtocolConsent, eligibility, visits, endpoints, deviations and source context
Core systemsEDC / eCRF / eSourceClinical observations, forms, queries, audit trails and data changes
ExternalLabs / eCOA / IRTLaboratory, outcomes, randomisation, dosing and vendor-supplied data
SafetySafety / Imaging / DevicesSafety reconciliation, imaging, sensors and specialised assessments
ControlStandards, Rules & ReconciliationMetadata, validation, cross-source checks, exceptions and remediation
UseAnalysis, Reporting & SubmissionCurated datasets, traceability, review evidence and decision-ready outputs
Primary buyersClinical data management, clinical operations, biometrics, quality, R&D data and clinical systems leaders
Typical data landscapeEDC/eSource, labs, eCOA, IRT, safety, imaging, device feeds, standards, analysis and reporting
Material risksMissing or inconsistent critical data, late reconciliation, unclear lineage, weak controls and recurring exceptions
Target capabilityStudy-specific critical-data ownership, measurable quality rules, traceable evidence and sustainable monitoring
1
Why Clinical Trial Data Quality Becomes an Enterprise Risk
Trial data is produced across participants, sites, sponsors, CROs, specialist vendors and technology platforms. Quality problems become more consequential when they affect participant protection, protocol decisions, endpoint reliability, safety review, database lock, statistical analysis, regulatory evidence or inspection readiness.
Laboratory, eCOA, IRT, safety, imaging or device data can surface mismatches only after downstream review has already begun.
Equivalent data can be validated against different definitions, code sets, thresholds or timing rules, creating avoidable inconsistency.
Checks, queries, remediation, approvals and rationale may be distributed across systems, spreadsheets, tickets and email rather than one traceable control view.
One-time cleaning resolves records but not the process, interface, specification or ownership failure that generated the defect.
Reviewers cannot easily follow a critical value from source and transformation through curated datasets, analysis and reporting use.
Quality risk is compressed into late cleaning and reconciliation cycles instead of monitored throughout collection, integration and review.
Study teams use different quality indicators, exception categories and reporting practices, making cross-study governance difficult.
From reactive cleaning to a controlled trial-data capability
Current State — Quality Discovered Late
- Rules concentrated in downstream review
- Multiple vendor files and local reconciliations
- Critical-data rationale is implicit
- Issues are tracked without consistent severity
- Lineage and evidence assembled on demand
- Recurring defects return in later cycles
Target State — Quality Designed Into the Data Flow
- Critical-to-quality factors drive priorities
- Rules execute at appropriate control points
- Reconciliation is mapped and owned
- Exceptions carry severity, owner and evidence
- Lineage connects source to intended use
- Monitoring supports continual improvement
Find the Trial-Data Risks Before They Converge at Database Lock
Start with the protocol, critical data, systems, vendor feeds, reconciliation points, existing controls and known issue patterns.
2
What the Clinical Trial Data Quality Service Covers
The engagement follows the trial data path rather than treating quality as a single-system activity. Scope can start with one study, one data domain or one material risk and expand across a programme or portfolio.
Protocol & CTQ ContextObjectives, endpoints, safety and critical processes
Data-Flow MappingSources, interfaces, transformations and consumers
Critical-Data RegisterElements, intended use, risk and ownership
Rules & ControlsLogic, thresholds, timing, evidence and response
Reconciliation & StandardsCross-source checks, metadata and mappings
Issues & RemediationSeverity, root cause, action, ageing and closure
Monitoring & ScorecardsCoverage, trends, exceptions and management views
Governance & OperationsRoles, review cadence, change and continuous improvement
Clinical Trial Data Taxonomy — Where Quality Controls Need Context
| Participant & Site | Protocol & Visits | Clinical & Endpoint | Safety & Medical | External / Vendor | Standards & Metadata | Analysis & Evidence |
|---|---|---|---|---|---|---|
| Participant identifiers Consent status Eligibility Site/investigator Visit occurrence |
Schedule and protocol Visit windows Protocol deviations Randomisation Investigational product |
eCRF/eSource Primary/secondary endpoints Clinical assessments Concomitant medication Medical history |
AE/SAE data Safety reconciliation Medical coding Laboratory safety Clinical review flags |
Laboratory eCOA IRT Imaging Devices/wearables Specialist vendor feeds |
CRF metadata Controlled terminology Code lists Mappings SDTM/ADaM/Define metadata where applicable |
Curated datasets Lineage Quality evidence Analysis datasets Tables/listings/figures Submission support |
3
Trial Data Architecture With Quality Risks and Control Points Visible
The target design makes quality expectations explicit across capture, integration, standardisation, reconciliation, curation and downstream use. The architecture below is illustrative; a client design is derived from the actual protocol, systems, vendors and operating responsibilities.
1. Participant / Site
- Consent & eligibility
- Visits & assessments
- Protocol context
- Source documentation
2. Core Clinical Systems
- EDC / eCRF
- eSource
- CTMS context
- Audit trails
3. External Sources
- Labs
- eCOA / IRT
- Safety / imaging
- Devices / vendors
4. Integration & Staging
- Transfers
- Schema checks
- Reference values
- Ingestion evidence
5. Quality & Reconciliation
- Business rules
- Cross-source checks
- Exceptions
- Root cause
6. Curated / Standards Layer
- Standard mappings
- Metadata
- Lineage
- Analysis-ready data
7. Decision & Evidence Use
- Clinical review
- Safety / biometrics
- Reporting
- Submission / inspection
Critical-data ownershipAccess & change controlRule/version governanceLineage & audit evidenceIssue & escalation workflowMonitoring & review cadence
Business Priority → Data Risk → Control Mapping
| Business priority | Trial-data scenario | Quality risk | Potential control response | Evidence to retain |
|---|---|---|---|---|
| Participant protection | Eligibility, consent, dosing or critical safety information | Missing, late or inconsistent material data | Critical-element rules, timing checks, reconciliation, exception escalation | Rule results, queries, resolution rationale, review evidence |
| Endpoint reliability | Primary endpoint or key assessment variables | Invalid values, timing errors, inconsistent derivation inputs | Protocol-aware validation, visit-window logic, cross-source reconciliation | Specifications, rule version, exceptions, approvals and lineage |
| Database lock readiness | Outstanding queries, reconciliations and vendor feeds | Late surprises or unresolved critical issues | Readiness scorecard, ageing thresholds, dependency checks and ownership | Open/closed issue register, status trend, lock decision support |
| Multi-vendor consistency | Lab, eCOA, IRT, safety, imaging and device data | Different identifiers, formats, timestamps or reference values | Data contracts, standardisation, ingestion controls, cross-source checks | Transfer specs, mapping, validation logs and reconciliation outcomes |
| Analysis traceability | Source-to-curated-to-analysis transformation | Unclear origin or transformation of critical variables | Metadata, lineage, controlled mappings and change records | Transformation specs, lineage maps, test evidence and approvals |
| Portfolio oversight | Multiple studies using different quality practices | Incomparable KPIs and inconsistent issue severity | Common quality taxonomy, minimum control set, study-specific exceptions | Portfolio scorecards, standards, deviations and governance decisions |
Design Controls Around the Trial Data That Actually Matters
Connect protocol intent, critical-to-quality factors, data elements, business rules, control points, exceptions, owners and monitoring.
4
Critical-to-Quality Data, Rules and Controls
A useful quality framework creates traceability from the intended use of data through the rule, control, exception response and evidence. It also distinguishes what must be prevented, what can be detected, what needs human review and what requires remediation.
Data ElementProtocol or operationally material field
Intended UseSafety, endpoint, analysis or decision purpose
Quality DimensionAccuracy, completeness, timeliness, validity and more
Business RuleTestable logic, tolerance and population
Control PointCapture, transfer, transform, reconcile or review
ExceptionSeverity, reason, owner and due action
Business ImpactParticipant, endpoint, lock, analysis or evidence risk
RemediationRecord correction and upstream root-cause action
MonitoringCoverage, trend, recurrence and control effectiveness
Illustrative Critical-Data Control Examples
| Illustrative data area | Why it may be critical | Example quality concern | Potential control pattern | Accountable review |
|---|---|---|---|---|
| Informed consent status and timing | Participant rights and authorised study participation | Missing evidence or timing inconsistent with study activity | Completeness and chronology checks with escalation | Clinical operations / quality / site oversight |
| Eligibility criteria | Study population and protocol compliance | Required evidence incomplete or contradictory | Rule set linked to protocol criteria and source review | Clinical / medical / data management |
| Primary endpoint variables | Core analysis and study objective | Missing, out-of-window or inconsistent measurement | Visit-window, range, completeness and cross-source rules | Clinical data / biometrics / medical |
| Investigational product exposure | Dose, treatment and exposure interpretation | Dose or timing mismatch across systems | EDC-to-IRT or dosing reconciliation and exception workflow | Clinical operations / data management |
| Serious adverse event data | Safety oversight and reconciliation | Mismatch between clinical and safety systems | Scheduled reconciliation, identifier checks and ageing controls | Safety / medical / clinical data |
| Central laboratory data | Safety or endpoint interpretation | Unit, reference range, visit or participant mismatch | Transfer validation, standardisation and reference-data controls | Clinical data / vendor management / medical |
| eCOA assessments | Patient-reported or clinician-reported outcomes | Missing assessments, timestamp issues or transfer gaps | Expected-event checks, timeliness monitoring and transfer reconciliation | Clinical / data management / vendor owner |
| Protocol deviations | Interpretation of conduct and analysis populations | Inconsistent categorisation or linkage to events | Controlled terminology, review workflow and cross-system reconciliation | Clinical operations / quality / biometrics |
Important: The examples above are not a universal critical-data list. Critical-to-quality factors and controls should be study-specific and derived from protocol objectives, participant-protection needs, intended data use, risk assessment, source characteristics and applicable regulatory requirements.
5
Regulatory and Standards Context for Trial-Data Quality
Depending on the study, product, sponsor, jurisdiction and data use, clinical-trial data quality may need to align with GCP, electronic-record expectations, clinical-trial regulations, submission standards and local requirements. The following sources are current reference points for scoping; they are not a substitute for legal or regulatory interpretation.
ICH E6(R3) Good Clinical Practice
The final E6(R3) Principles and Annex 1 were adopted on 6 January 2025. For data-quality work, the practical relevance is a risk-proportionate quality approach, clear responsibilities, fit-for-purpose systems and reliable evidence supporting trial conduct and results.
Review official ICH E6(R3) →ICH E8(R1) General Considerations
E8(R1) frames quality by design around factors critical to participant protection and reliable, meaningful results. It supports prospective focus on what matters rather than relying only on retrospective cleaning, review and audit.
Review official ICH E8(R1) →Electronic Systems, Records and Signatures
FDA’s October 2024 final guidance addresses electronic systems, electronic records and electronic signatures in clinical investigations and recommendations for trustworthy and reliable electronic evidence.
Review FDA guidance →Computerised Systems and Electronic Data
EMA’s 2023 GCP guideline covers computerised systems and electronic data in clinical trials, including validation, data integrity, security, user management, audit trails and considerations for specific clinical systems.
Review EMA guideline →EU Clinical Trials Regulation
From 31 January 2025, clinical trials in the EU/EEA must be conducted in accordance with Regulation (EU) No 536/2014 using CTIS. Data and evidence design should reflect the actual study’s regulatory pathway and member-state responsibilities.
Review European Commission information →New Drugs and Clinical Trials Rules, 2019
For India-relevant clinical trials, the New Drugs and Clinical Trials Rules, 2019 and subsequent CDSCO notices, FAQs and amendments form an important part of the regulatory context. Applicability should be confirmed for the specific trial and product.
Review current CDSCO rules and notices →Submission Metadata and Data Standards
Where applicable, standards such as SDTM, ADaM and Define-XML can support structured, traceable submission data. The correct versions and implementation guides depend on the regulator, programme and submission context.
Review CDISC Define-XML →Control boundary: DataConsultant can help map applicable requirements to data flows, critical elements, controls, metadata, lineage, issue processes and operating responsibilities. The service does not provide legal advice, regulatory certification, statutory audit, sponsor medical oversight or guaranteed compliance.
Turn Data-Quality Findings Into an Implementable Control Backlog
Prioritise rules, reconciliation, metadata, lineage, issue workflows, scorecards and ownership by material trial risk and delivery dependency.
6
How DataConsultant Delivers Clinical Trial Data Quality Work
The method starts with protocol and decision context, moves through evidence and control design, and continues into implementation or operation when those activities are in scope. Each stage records assumptions, limitations, owners and decisions.
Scope the Study ContextObjectives, trial phase, systems, vendors, jurisdictions, stakeholders and quality concerns.
Map the Data FlowSource, collection, transfer, integration, transformation, reconciliation, curation and use.
Prioritise Critical DataCTQ factors, critical elements, intended use, materiality, ownership and known risks.
Profile & DiagnoseEvidence review, profiling, issue patterns, rule coverage, reconciliation and lineage gaps.
Design ControlsRule logic, thresholds, preventive/detective controls, evidence, escalation and acceptance.
Validate & PrioritiseBusiness review, technical feasibility, risk ranking, dependencies and implementation sequencing.
Implement & PilotConfiguration, pipeline checks, workflows, dashboards, testing, pilot evidence and handover.
Operate & ImproveMonitoring, issue review, root cause, rule change, scorecards, governance and continuous improvement.
Decision-Ready Deliverables for Clinical, Data, Quality and Technology Teams
Evidence, risks, control coverage, issue patterns, constraints and material gaps.
Sources, transfers, transformations, reconciliations, systems, owners and consumers.
CTQ linkage, intended use, risk rationale, source, owner and downstream dependency.
Dimensions, logic, population, threshold, severity, execution point and evidence.
Preventive/detective controls, cross-source checks, frequency, operator and response.
Exceptions, root causes, priority, dependency, accountable owner and acceptance criteria.
Coverage, pass rates, ageing, recurrence, critical exceptions and management views.
Decision rights across clinical, data, safety, quality, biometrics, technology and vendors.
Prioritised controls, technical changes, pilots, dependencies, review gates and mobilisation.
Monitoring, issue workflow, rule change, reporting cadence, escalation and knowledge transfer.
What DataConsultant Needs From the Client
Evidence & data context
Enough evidence to understand the real trial-data path
Inputs are adapted to the engagement. Missing artefacts are documented as limitations rather than silently assumed.
- Protocol, data-management plan and data-review plan where shareable
- System, vendor and data-transfer inventory
- CRF/data-collection metadata and specifications
- Existing validation rules, reconciliation procedures and quality reports
- Issue/query logs, deviations, audit observations or known defect patterns where relevant
- Representative data or profiling access under approved privacy and security controls
People & decisions
Accountable stakeholders who can confirm purpose and materiality
Data quality cannot be defined only by technology teams because fitness for use depends on clinical, operational, analytical and quality context.
- Clinical data management and clinical operations
- Medical, safety and pharmacovigilance stakeholders where relevant
- Biometrics, biostatistics and statistical programming stakeholders
- GCP quality, regulatory operations and inspection-readiness teams
- Clinical systems, integration, data engineering and security teams
- Vendor owners, data stewards and accountable programme leadership
7
From Assessment to Implementation and Sustainable Quality Operations
The service does not need to stop at findings. When separately scoped, DataConsultant can help translate control designs into platform requirements, quality rules, pipelines, workflows, dashboards, metadata and operating practices, while working within the client’s validation and change-control environment.
DesignRules, controls, data contracts, lineage, workflow, KPIs and ownership.
MobilisePrioritised backlog, responsibilities, environments, test approach and decision gates.
ImplementConfiguration, integration controls, monitoring views, issue routing and documentation.
OperateRule execution, exception triage, scorecards, reconciliations, evidence and reporting.
ImproveRoot-cause removal, rule tuning, portfolio standardisation and controlled change.
Translate the control model into working capability
Implementation scope can include requirements and configuration support across the client’s existing EDC, integration, data-quality, metadata, lineage, BI and workflow tooling.
- Rule and control technical specifications
- Data-transfer and ingestion validation
- Cross-source reconciliation logic
- Metadata and lineage capture
- Quality dashboards and management reporting
- Issue workflow, severity and escalation design
- Test cases, acceptance evidence and release support
- Training and operational handover
Keep quality visible after the project closes
Ongoing support can be advisory, co-managed or operational depending on responsibilities, access and the client’s quality operating model.
- Critical-rule monitoring and exception triage
- Issue ageing and root-cause review
- Vendor-feed and reconciliation monitoring
- Rule/version maintenance and controlled change
- Quality scorecards and governance reporting
- Periodic critical-data and coverage review
- Portfolio harmonisation and continuous improvement
- Knowledge transfer and capability development
Business Outcomes the Capability Is Designed to Support
- Earlier visibility of defects affecting critical trial data
- Clearer ownership of quality rules, exceptions and remediation
- More consistent reconciliation across systems and external feeds
- Stronger traceability from source through analysis and reporting use
- Better evidence for quality review, inspection preparation and decision support
- Reduced dependence on late manual cleaning as the primary quality mechanism
- More comparable quality reporting across studies and programmes
- A repeatable operating model for monitoring, escalation and continuous improvement
Scope Clinical Trial Data Quality by Study, Programme or Portfolio
Share the trial phase, systems, data feeds, critical issues, jurisdictions and implementation expectations so the engagement can be sized responsibly.
8
Engagement Models and Commercial Clarity
DataConsultant does not publish a fixed price for this Clinical Trial Data Quality service. Pricing is custom-scoped because a single-study quality assessment, a multi-vendor control design, a portfolio remediation programme and an ongoing quality operation have materially different evidence, access, delivery and responsibility requirements.
Evidence-led review of one study, risk area or data flow to identify material quality gaps and prioritised next actions.
Commercial basis: Custom scope & pricingRequest a Quote →Define CTQ linkage, critical elements, rules, control points, reconciliation, evidence and operating responsibilities.
Commercial basis: Custom scope & pricingRequest a Quote →Translate approved designs into platform requirements, configured rules, workflows, dashboards, test evidence and pilot rollout.
Commercial basis: Custom scope & pricingRequest a Quote →Standardise quality taxonomy, controls, issue management and reporting across multiple studies, systems or vendors.
Commercial basis: Custom scope & pricingRequest a Quote →Support monitoring, exception triage, scorecards, rule maintenance, root-cause follow-up and continuous improvement.
Commercial basis: Custom scope & pricingRequest a Quote →What Affects Scope, Timeline and Price
Number and phase of studies
Countries and regulatory pathways
Sites, CROs and specialist vendors
EDC/eSource and clinical systems
External data feeds and interfaces
Critical-data elements and rule count
Data volume and profiling depth
Reconciliation and lineage complexity
Existing quality evidence and issue backlog
Implementation and validation responsibilities
Stakeholders, workshops and review cycles
Ongoing monitoring and managed support
Timeline: confirmed after scoping. Third-party platform, cloud, validation-tool or vendor charges: separate from DataConsultant consulting fees unless explicitly included in a written proposal. No fixed fee or duration is implied by this page.
9
When This Service Is — and Is Not — the Right Starting Point
Clinical Trial Data Quality is most useful when the problem crosses data, process, controls, systems and ownership. A narrower specialist service may be more appropriate when the requirement is isolated.
Good fit when
- Quality issues recur across studies, systems or vendors
- Critical data and quality priorities are not consistently defined
- Reconciliation is manual, late or difficult to evidence
- Database-lock readiness depends on fragmented status reporting
- Lineage from source to analysis or reporting is unclear
- Portfolio teams need consistent quality controls and scorecards
- Implementation support is needed after assessment or control design
Another approach may be better when
- The need is only one-off record cleansing with no control or process change
- The requirement is statistical analysis or programming only
- A formal legal opinion, regulatory certification or statutory audit is required
- A proprietary platform vendor must perform all configuration
- Cybersecurity penetration testing is the primary requirement
- No accountable study, data or quality stakeholders can participate
- Required evidence or access cannot be made available under approved controls
Why DataConsultant for This Clinical-Data Problem
Quality rules are tied to protocol intent, critical data, participant and endpoint implications rather than a generic rule library.
Assessment follows data across capture, vendor transfer, integration, reconciliation, curation, analysis and evidence use.
Ownership, severity, evidence, escalation, exceptions and rule change are designed with the control itself.
Recommendations work with the client’s current clinical and data estate rather than forcing a predetermined tool choice.
Approved designs can move into technical specifications, pilot rollout, testing, handover and managed operations when scoped.
Findings, assumptions, limitations, decisions, acceptance criteria and handover artefacts remain visible throughout the engagement.
11
Clinical Trial Data Quality FAQs
These answers explain typical scope, controls, standards, delivery, implementation and commercial treatment. Final responsibilities and outputs are confirmed in the engagement scope.
What is Clinical Trial Data Quality consulting?
Clinical Trial Data Quality consulting is a structured service for assessing whether trial data is fit for protocol execution, safety oversight, analysis, reporting and applicable submission or inspection needs. It connects critical-to-quality factors, critical data elements, source systems, business rules, controls, issue workflows, ownership, lineage and monitoring rather than treating quality as one-time data cleaning.
Which parts of the clinical-trial data flow can be assessed?
Scope can cover protocol-driven data collection, eCRF or EDC data, eSource, laboratory feeds, eCOA, IRT or randomisation data, safety data, imaging and device feeds, medical coding, reconciliation, query management, standards and metadata, analysis-ready datasets, reporting interfaces and supporting lineage or audit evidence. The exact systems and processes are confirmed during discovery.
How do you identify critical data elements and critical-to-quality factors?
The engagement links protocol objectives, participant protection, key endpoints, safety information, operational decisions and applicable requirements to the data that materially supports them. Candidate critical elements are reviewed with clinical, data-management, medical, safety, biostatistics, quality and technology stakeholders before rule coverage and control priorities are agreed.
Which data-quality dimensions do you use?
Dimensions may include accuracy, completeness, consistency, validity, timeliness, uniqueness, integrity and traceability. The service does not apply identical thresholds to every field. Rules and tolerances are defined according to intended use, materiality, protocol context, source characteristics, risk and applicable requirements.
Can the service help before database lock?
Yes. A scoped engagement can review unresolved quality risks, reconciliation gaps, critical rule coverage, issue ageing, lineage, vendor-feed dependencies and evidence readiness before lock. It does not replace sponsor decision-making, statistical review, medical review or formal quality assurance responsibilities.
Can DataConsultant work with EDC, eCOA, IRT, laboratory, safety and other vendor data?
Yes. The work is platform-neutral and can assess data flows, interfaces, transformations, metadata, controls and evidence across existing clinical systems and vendor feeds. Proprietary system changes, validation activities or vendor-specific configuration are included only when access, responsibilities and scope are explicitly agreed.
How are CDISC standards considered?
Where relevant to the study and submission pathway, the service can assess standards and metadata alignment for formats such as SDTM, ADaM and Define-XML, including traceability between source, transformation and downstream use. The applicable standard versions and regulator expectations should be confirmed for each programme rather than assumed globally.
How do ICH E6(R3) and ICH E8(R1) affect the approach?
The service can use quality-by-design and risk-proportionate principles to focus attention on factors that are critical to participant protection and reliable trial results. Regulatory interpretation remains the client’s responsibility with appropriate clinical, quality, regulatory and legal specialists; DataConsultant supports data, governance, control and implementation readiness.
Can you support clinical-trial data quality for India, the EU and the United States?
The service can account for jurisdiction-specific data and evidence requirements where they are relevant to the agreed scope. Current sources such as CDSCO rules and guidance, the EU Clinical Trials Regulation and CTIS framework, FDA guidance, EMA guidance and ICH standards can inform the control context. Applicability must be confirmed for the specific sponsor, study, product, geography and use case.
What deliverables can we expect?
Typical outputs can include a current-state assessment, trial-data flow and lineage map, critical-data register, quality-rule catalogue, control matrix, reconciliation map, issue and remediation backlog, quality scorecard specification, governance and RACI model, implementation backlog, acceptance criteria and an operating or monitoring playbook. Final deliverables are agreed during scoping.
Can DataConsultant implement the recommended controls?
Implementation support can be scoped separately for rule configuration, pipeline controls, data-quality tooling, metadata and lineage, dashboards, workflow automation, testing, pilot rollout, governance mobilisation, training and delivery assurance. Production changes remain subject to the client’s validation, change-control, security and release processes.
Can you provide ongoing clinical-trial data quality operations?
Yes. Ongoing support can include quality-rule monitoring, exception triage, scorecards, issue ageing, root-cause tracking, control maintenance, vendor-feed monitoring, periodic critical-data review, evidence reporting and continuous improvement. Service boundaries, responsibilities and escalation paths are defined before transition.
How long does a Clinical Trial Data Quality engagement take?
Timeline is confirmed after scoping. It depends on the number of studies, sites, systems, vendors and data domains; protocol complexity; evidence quality; stakeholder availability; regulatory context; the depth of profiling and control design; and whether implementation, validation support or ongoing operations are included.
How is Clinical Trial Data Quality pricing determined?
DataConsultant uses custom scope and pricing for this service. Commercial scope can vary with the number of studies, systems, data feeds, critical elements, jurisdictions, stakeholders, workshops, profiling depth, control coverage, implementation responsibilities, deliverables, onsite requirements and ongoing support. A quote is prepared after the required outcomes and dependencies are understood.
What should we prepare before starting?
Useful inputs include the protocol and data-management plan where shareable, system and vendor inventory, data-flow diagrams, data specifications, CRF or data-collection metadata, quality checks, reconciliation procedures, issue and query logs, audit or inspection observations where relevant, lineage information, standards documentation, sample or representative data, current scorecards and access to accountable clinical, data, quality and technology stakeholders.
Clinical Trial Data Quality Enquiry
Request a Clinical Trial Data Quality Scope Review
Share your contact details and requirement. DataConsultant can review the likely evidence, stakeholders, scope factors and appropriate next step.